Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.44 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.37 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.35 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL7007959 | 0.90 | OPRM1 (0.46) | OPRL1OPRM1OPRD1OPRK1SLC18A3 | |
| Fumaric Acid SCHEMBL7007957 | 0.90 | OPRM1 (0.46) | OPRL1OPRM1OPRD1OPRK1SLC18A3 | |
| Fumaric Acid SCHEMBL7883822 | 0.84 | OPRM1 (0.47) | OPRL1OPRM1OPRD1OPRK1SLC18A3 | |
| Fumaric Acid SCHEMBL7883803 | 0.84 | OPRM1 (0.47) | OPRL1OPRM1OPRD1OPRK1SLC18A3 | |
| Fumaric Acid SCHEMBL7878795 | 0.84 | OPRM1 (0.47) | OPRL1OPRM1OPRD1OPRK1SLC18A3 | |
| Fumaric Acid SCHEMBL7886498 | 0.84 | OPRM1 (0.47) | OPRL1OPRM1OPRD1OPRK1SLC18A3 | |
| Fumaric Acid SCHEMBL7886495 | 0.84 | OPRM1 (0.47) | OPRL1OPRM1OPRD1OPRK1SLC18A3 | |
| Fumaric Acid SCHEMBL7883826 | 0.84 | OPRM1 (0.47) | OPRL1OPRM1OPRD1OPRK1SLC18A3 | |
| Fumaric Acid SCHEMBL7878800 | 0.84 | OPRM1 (0.47) | OPRL1OPRM1OPRD1OPRK1SLC18A3 | |
| Fumaric Acid SCHEMBL7883810 | 0.84 | OPRM1 (0.47) | OPRL1OPRM1OPRD1OPRK1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642247-B2 | Treting anxiety, stress, depression, trauma, Alzheimer's mediated memory loss, epilepsy, arterial blood pressure disorders, obesity, acute pain, chronic pain, Na+ excretion, control of water balance, and symptoms associated with drug | HOFFMAN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-0963985-B1 | Di-or triaza-spiro(4,5)decane derivatives | HOFFMANN LA ROCHE (CH) | 2003-03-12 | — | — | EP | disclosed |
| EP-0963985-A2 | Di-or triaza-spiro(4,5)decane derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176701-A1 | DI-OR TRIAZA-SPIRO [4,5] DECANE DERIVATIVES | NPY4R, NPY1R, OXER1 | HRH3 536/4885OPRL1 36/4885OPRM1 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.